- Home
- AGIO vs AI Comparison
AGIO vs AI Comparison
Compare AGIO & AI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- AI
- Stock Information
- Founded
- AGIO 2007
- AI 2009
- Country
- AGIO United States
- AI United States
- Employees
- AGIO N/A
- AI N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- AI Computer Software: Prepackaged Software
- Sector
- AGIO Health Care
- AI Technology
- Exchange
- AGIO Nasdaq
- AI Nasdaq
- Market Cap
- AGIO 2.4B
- AI 2.4B
- IPO Year
- AGIO 2013
- AI 2020
- Fundamental
- Price
- AGIO $40.16
- AI $15.27
- Analyst Decision
- AGIO Strong Buy
- AI Hold
- Analyst Count
- AGIO 4
- AI 15
- Target Price
- AGIO $59.33
- AI $24.62
- AVG Volume (30 Days)
- AGIO 567.8K
- AI 5.7M
- Earning Date
- AGIO 10-30-2025
- AI 12-08-2025
- Dividend Yield
- AGIO N/A
- AI N/A
- EPS Growth
- AGIO N/A
- AI N/A
- EPS
- AGIO N/A
- AI N/A
- Revenue
- AGIO $44,791,000.00
- AI $372,104,000.00
- Revenue This Year
- AGIO $25.57
- AI N/A
- Revenue Next Year
- AGIO $153.24
- AI $11.61
- P/E Ratio
- AGIO N/A
- AI N/A
- Revenue Growth
- AGIO 36.26
- AI 14.34
- 52 Week Low
- AGIO $23.42
- AI $14.70
- 52 Week High
- AGIO $62.58
- AI $45.08
- Technical
- Relative Strength Index (RSI)
- AGIO 45.66
- AI 33.78
- Support Level
- AGIO $38.90
- AI $16.84
- Resistance Level
- AGIO $44.10
- AI $17.59
- Average True Range (ATR)
- AGIO 1.72
- AI 0.70
- MACD
- AGIO -0.44
- AI -0.27
- Stochastic Oscillator
- AGIO 24.58
- AI 6.39
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About AI C3.ai Inc.
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Platform, which is an end-to-end application development and runtime environment for designing, developing, and deploying AI applications: C3 AI Applications, which is a portfolio of pre-built, extensible, industry-specific, and application-specific Enterprise AI applications: and C3 Generative AI, which combines the utility of large language models. Geographically the company derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and the Rest of the World.